Cetera Investment Advisers Makes New $306,000 Investment in Royalty Pharma PLC $RPRX

Key Points

• Cetera Investment Advisers has acquired a new position in Royalty Pharma PLC, purchasing 9,826 shares valued at approximately $306,000.
• Institutional investors and hedge funds collectively own 54.35% of Royalty Pharma's stock, with significant increases in positions from various firms over the last quarters.
• Royalty Pharma recently announced a quarterly dividend of $0.22 per share, with an annualized yield of 2.4% and a payout ratio of 50.87%.

Cetera Investment Advisers acquired a new position in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,826 shares of the biopharmaceutical company's stock, valued at approximately $306,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Louisbourg Investments Inc. acquired a new position in Royalty Pharma during the first quarter valued at approximately $28,000. MassMutual Private Wealth & Trust FSB grew its holdings in Royalty Pharma by 76.4% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 956 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 414 shares during the last quarter. Allworth Financial LP boosted its position in shares of Royalty Pharma by 41.6% in the first quarter. Allworth Financial LP now owns 1,539 shares of the biopharmaceutical company's stock valued at $49,000 after acquiring an additional 452 shares during the period. Transce3nd LLC bought a new stake in shares of Royalty Pharma in the fourth quarter valued at approximately $61,000. Finally, Friedenthal Financial bought a new stake in shares of Royalty Pharma in the first quarter valued at approximately $77,000. Institutional investors and hedge funds own 54.35% of the company's stock.

Royalty Pharma Trading Down 1.5%

NASDAQ:RPRX traded down $0.57 on Thursday, hitting $36.31. 2,529,890 shares of the stock were exchanged, compared to its average volume of 2,976,985. The stock has a market capitalization of $21.17 billion, a price-to-earnings ratio of 20.99, a P/E/G ratio of 2.41 and a beta of 0.55. Royalty Pharma PLC has a 52 week low of $24.05 and a 52 week high of $38.00. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.26 and a current ratio of 1.26. The company's 50-day moving average price is $36.12 and its 200 day moving average price is $33.83.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.04. The firm had revenue of $578.67 million during the quarter, compared to analysts' expectations of $750.06 million. Royalty Pharma had a return on equity of 25.54% and a net margin of 44.23%. On average, equities research analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a $0.22 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.4%. Royalty Pharma's dividend payout ratio is 50.87%.

Analyst Ratings Changes

RPRX has been the subject of several research reports. Morgan Stanley increased their price objective on Royalty Pharma from $51.00 to $54.00 and gave the company an "overweight" rating in a research report on Thursday, July 10th. Citigroup raised their target price on Royalty Pharma from $40.00 to $42.00 and gave the stock a "buy" rating in a research report on Tuesday, July 22nd. Finally, Wall Street Zen raised Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. One research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $48.00.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.